Protagonist “delighted” with trial failure
Development of the ulcerative colitis project PN-943 continues.
Protagonist seeks an Ideal readout
A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.
Doomsday for Allakos
If lirentelimab reduces eosinophils in diseases characterised by eosinophil accumulation, why doesn’t it work?
Genfit rises from the ashes of elafibranor
Ipsen hopes to draw a line under its earlier deal-making snafu with a bet on Genfit, and investors have just over a year’s wait for the proof.
Pfizer starts to put its vaccine cash to use
After years of U-turns Arena's pivot to bowel disease pays off, with a $6.7bn takeout bid.
